Karuna Therapeutics (KRTX) Short Interest Ratio & Short Volume → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free KRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Karuna Therapeutics Short Interest DataCurrent Short Volume1,970,000 sharesPrevious Short Volume2,110,000 sharesChange Vs. Previous Month-6.64%Dollar Volume Sold Short$618.52 millionShort Interest Ratio / Days to Cover2.3Last Record DateFebruary 29, 2024Outstanding Shares38,148,000 sharesPercentage of Shares Shorted5.16%Today's Trading Volume5 sharesAverage Trading Volume832,048 sharesToday's Volume Vs. Average0% Short Selling Karuna Therapeutics ? Sign up to receive the latest short interest report for Karuna Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKRTX Short Interest Over TimeKRTX Days to Cover Over TimeKRTX Percentage of Float Shorted Over Time Ad DTIYou missed the class - here’s your second chanceIt’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore…Click here and I’ll give you the details. Karuna Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/29/20241,970,000 shares $618.52 million -6.6%N/A2.3 $313.97 2/15/20242,110,000 shares $673.91 million +24.9%N/A2.5 $319.39 1/31/20241,690,000 shares $529.68 million +15.8%N/A2.1 $313.42 1/15/20241,460,000 shares $462.46 million -4.6%N/A2 $316.75 12/31/20231,530,000 shares $484.26 million -24.3%N/A2.5 $316.51 12/15/20232,020,000 shares $443.94 million -1.5%N/A4.7 $219.77 Get the Latest News and Ratings for KRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20232,050,000 shares $391.98 million +7.3%N/A7.7 $191.21 11/15/20231,910,000 shares $328.06 million +3.8%N/A8.1 $171.76 10/31/20231,840,000 shares $306.56 million +12.2%N/A7.7 $166.61 10/15/20231,640,000 shares $280.46 million -1.8%N/A6.5 $171.01 9/30/20231,670,000 shares $282.38 million +18.4%N/A6.6 $169.09 9/15/20231,410,000 shares $255.07 million +4.4%N/A5.3 $180.90 8/31/20231,350,000 shares $253.48 million -6.9%N/A3.9 $187.76 8/15/20231,450,000 shares $260.26 million +16.0%N/A4 $179.49 7/31/20231,250,000 shares $249.71 million -1.6%N/A3.3 $199.77 7/15/20231,270,000 shares $269.01 million -4.5%N/A3.3 $211.82 6/30/20231,330,000 shares $288.41 million -37.0%N/A3.3 $216.85 6/15/20232,110,000 shares $503.34 million -0.9%N/A5 $238.55 5/31/20232,130,000 shares $482.55 million +2.4%N/A5.2 $226.55 5/15/20232,080,000 shares $479.69 million -2.4%N/A5 $230.62 4/30/20232,130,000 shares $422.68 million +1.4%N/A5.1 $198.44 4/15/20232,100,000 shares $383.54 million -1.9%N/A5.2 $182.64 3/31/20232,140,000 shares $388.71 million +22.3%N/A5.5 $181.64 3/15/20231,750,000 shares $327.37 million +0.6%N/A4.8 $187.07 2/28/20231,740,000 shares $346.99 million +4.2%6.1%5.8 $199.42 2/15/20231,670,000 shares $324.23 million No Change5.9%5.8 $194.15 1/31/20231,670,000 shares $332.98 million -0.6%6.0%5.8 $199.39 1/15/20231,680,000 shares $337.26 million -2.9%6.0%5.7 $200.75 12/30/20221,730,000 shares $339.95 million +10.9%6.3%5.8 $196.50 12/15/20221,560,000 shares $312 million +6.1%5.6%4.8 $200.00 11/30/20221,470,000 shares $345.91 million -13.5%5.4%4.1 $235.31 11/15/20221,700,000 shares $392.31 million +4.9%6.2%4.8 $230.77 10/31/20221,620,000 shares $355.33 million No Change6.2%3.6 $219.34 10/15/20221,620,000 shares $333.56 million +14.9%6.4%3 $205.90 9/30/20221,410,000 shares $317.15 million -23.4%5.6%2.7 $224.93 9/15/20221,840,000 shares $449.07 million -1.1%7.3%3.5 $244.06 8/31/20221,860,000 shares $474.41 million -9.7%7.6%3.6 $255.06 8/15/20222,060,000 shares $563.84 million +36.4%8.4%4.2 $273.71 7/31/20221,510,000 shares $196.68 million +6.3%7.0%3.8 $130.25 7/15/20221,420,000 shares $191.97 million +5.2%6.6%4.7 $135.19You missed the class - here’s your second chance (Ad)It’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore…Click here and I’ll give you the details. KRTX Short Interest - Frequently Asked Questions What is Karuna Therapeutics' current short interest? Short interest is the volume of Karuna Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 29th, traders have sold 1,970,000 shares of KRTX short. Learn More on Karuna Therapeutics' current short interest. What is a good short interest ratio for Karuna Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KRTX shares currently have a short interest ratio of 2.0. Learn More on Karuna Therapeutics's short interest ratio. Which institutional investors are shorting Karuna Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Karuna Therapeutics: UBS Group AG. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Karuna Therapeutics' short interest increasing or decreasing? Karuna Therapeutics saw a decrease in short interest in February. As of February 29th, there was short interest totaling 1,970,000 shares, a decrease of 6.6% from the previous total of 2,110,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Karuna Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Karuna Therapeutics: Dr. Reddy's Laboratories Limited (0.45%), Sarepta Therapeutics, Inc. (5.15%), Viatris Inc. (3.55%), United Therapeutics Co. (9.96%), BeiGene, Ltd. (1.92%), Catalent, Inc. (3.97%), BioMarin Pharmaceutical Inc. (1.94%), Teva Pharmaceutical Industries Limited (1.04%), Roivant Sciences Ltd. (8.18%), Viking Therapeutics, Inc. (10.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks. What does it mean to sell short Karuna Therapeutics stock? Short selling KRTX is an investing strategy that aims to generate trading profit from Karuna Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Karuna Therapeutics? A short squeeze for Karuna Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KRTX, which in turn drives the price of the stock up even further. How often is Karuna Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KRTX, twice per month. The most recent reporting period available is February, 29 2024. More Short Interest Resources from MarketBeat Related Companies: Dr. Reddy's Laboratories Short Interest Sarepta Therapeutics Short Interest Viatris Short Interest United Therapeutics Short Interest BeiGene Short Interest Catalent Short Interest BioMarin Pharmaceutical Short Interest Teva Pharmaceutical Industries Short Interest Roivant Sciences Short Interest Viking Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KRTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold